vs
AdvanSix Inc.（ASIX）与CLOVER HEALTH INVESTMENTS, CORP.（CLOV）财务数据对比。点击上方公司名可切换其他公司
CLOVER HEALTH INVESTMENTS, CORP.的季度营收约是AdvanSix Inc.的2.1倍（$749.2M vs $359.9M），CLOVER HEALTH INVESTMENTS, CORP.净利率更高（3.6% vs -0.8%，领先4.4%），CLOVER HEALTH INVESTMENTS, CORP.同比增速更快（62.0% vs 9.4%），过去两年CLOVER HEALTH INVESTMENTS, CORP.的营收复合增速更高（45.0% vs 3.4%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
克利弗健康投资公司是2014年成立的美国医疗保健企业，主营联邦医疗保险优势计划保险产品，是与美国政府直接签约合作的机构。目前公司为美国11个州的联邦医疗保险参保人提供健康管理服务，并已于2021年1月8日公开上市。
ASIX vs CLOV — 直观对比
营收规模更大
CLOV
是对方的2.1倍
$359.9M
营收增速更快
CLOV
高出52.7%
9.4%
净利率更高
CLOV
高出4.4%
-0.8%
两年增速更快
CLOV
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $749.2M |
| 净利润 | $-2.8M | $27.3M |
| 毛利率 | 7.6% | — |
| 营业利润率 | -0.7% | 3.6% |
| 净利率 | -0.8% | 3.6% |
| 营收同比 | 9.4% | 62.0% |
| 净利润同比 | -892.9% | — |
| 每股收益（稀释后） | $-0.11 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXCLOV
| Q1 26 | — | $749.2M | ||
| Q4 25 | $359.9M | $487.7M | ||
| Q3 25 | $374.5M | $496.6M | ||
| Q2 25 | $410.0M | $477.6M | ||
| Q1 25 | $377.8M | $462.3M | ||
| Q4 24 | $329.1M | $337.0M | ||
| Q3 24 | $398.2M | $331.0M | ||
| Q2 24 | $453.5M | $356.3M |
净利润ASIXCLOV
| Q1 26 | — | $27.3M | ||
| Q4 25 | $-2.8M | $-49.3M | ||
| Q3 25 | $-2.6M | $-24.4M | ||
| Q2 25 | $31.4M | $-10.6M | ||
| Q1 25 | $23.3M | $-1.3M | ||
| Q4 24 | $352.0K | $-22.1M | ||
| Q3 24 | $22.3M | $-9.2M | ||
| Q2 24 | $38.9M | $7.4M |
毛利率ASIXCLOV
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | 24.5% | ||
| Q2 24 | 17.9% | 30.3% |
营业利润率ASIXCLOV
| Q1 26 | — | 3.6% | ||
| Q4 25 | -0.7% | -10.1% | ||
| Q3 25 | -0.9% | -4.9% | ||
| Q2 25 | 7.7% | -2.2% | ||
| Q1 25 | 7.7% | -0.3% | ||
| Q4 24 | -3.9% | -6.4% | ||
| Q3 24 | 7.5% | -2.7% | ||
| Q2 24 | 11.5% | 2.0% |
净利率ASIXCLOV
| Q1 26 | — | 3.6% | ||
| Q4 25 | -0.8% | -10.1% | ||
| Q3 25 | -0.7% | -4.9% | ||
| Q2 25 | 7.7% | -2.2% | ||
| Q1 25 | 6.2% | -0.3% | ||
| Q4 24 | 0.1% | -6.6% | ||
| Q3 24 | 5.6% | -2.8% | ||
| Q2 24 | 8.6% | 2.1% |
每股收益（稀释后）ASIXCLOV
| Q1 26 | — | $0.05 | ||
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $1.15 | — | ||
| Q1 25 | $0.86 | — | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.82 | — | ||
| Q2 24 | $1.43 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $177.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $815.2M | $339.4M |
| 总资产 | $1.7B | $697.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASIXCLOV
| Q1 26 | — | $177.6M | ||
| Q4 25 | $19.8M | $78.3M | ||
| Q3 25 | $23.7M | — | ||
| Q2 25 | $18.4M | — | ||
| Q1 25 | $8.3M | — | ||
| Q4 24 | $19.6M | $194.5M | ||
| Q3 24 | $17.3M | $288.0M | ||
| Q2 24 | $12.1M | $254.8M |
股东权益ASIXCLOV
| Q1 26 | — | $339.4M | ||
| Q4 25 | $815.2M | $308.7M | ||
| Q3 25 | $818.2M | $340.9M | ||
| Q2 25 | $823.7M | $344.2M | ||
| Q1 25 | $794.4M | $336.1M | ||
| Q4 24 | $774.6M | $341.1M | ||
| Q3 24 | $766.4M | $342.2M | ||
| Q2 24 | $746.6M | $324.9M |
总资产ASIXCLOV
| Q1 26 | — | $697.7M | ||
| Q4 25 | $1.7B | $541.0M | ||
| Q3 25 | $1.7B | $559.7M | ||
| Q2 25 | $1.6B | $575.0M | ||
| Q1 25 | $1.6B | $583.7M | ||
| Q4 24 | $1.6B | $580.7M | ||
| Q3 24 | $1.5B | $653.0M | ||
| Q2 24 | $1.5B | $674.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | — |
| 自由现金流经营现金流 - 资本支出 | $36.1M | — |
| 自由现金流率自由现金流/营收 | 10.0% | — |
| 资本支出强度资本支出/营收 | 7.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $6.4M | — |
8季度趋势，按日历期对齐
经营现金流ASIXCLOV
| Q1 26 | — | — | ||
| Q4 25 | $63.7M | $-66.9M | ||
| Q3 25 | $26.6M | $12.1M | ||
| Q2 25 | $21.1M | $5.4M | ||
| Q1 25 | $11.4M | $-16.3M | ||
| Q4 24 | $64.2M | $34.8M | ||
| Q3 24 | $57.3M | $50.0M | ||
| Q2 24 | $50.2M | $44.8M |
自由现金流ASIXCLOV
| Q1 26 | — | — | ||
| Q4 25 | $36.1M | $-69.0M | ||
| Q3 25 | $66.0K | $11.4M | ||
| Q2 25 | $-7.2M | $4.8M | ||
| Q1 25 | $-22.6M | $-16.5M | ||
| Q4 24 | $29.8M | $33.3M | ||
| Q3 24 | $26.8M | $49.6M | ||
| Q2 24 | $16.7M | $44.4M |
自由现金流率ASIXCLOV
| Q1 26 | — | — | ||
| Q4 25 | 10.0% | -14.1% | ||
| Q3 25 | 0.0% | 2.3% | ||
| Q2 25 | -1.7% | 1.0% | ||
| Q1 25 | -6.0% | -3.6% | ||
| Q4 24 | 9.1% | 9.9% | ||
| Q3 24 | 6.7% | 15.0% | ||
| Q2 24 | 3.7% | 12.5% |
资本支出强度ASIXCLOV
| Q1 26 | — | — | ||
| Q4 25 | 7.7% | 0.4% | ||
| Q3 25 | 7.1% | 0.1% | ||
| Q2 25 | 6.9% | 0.1% | ||
| Q1 25 | 9.0% | 0.0% | ||
| Q4 24 | 10.4% | 0.5% | ||
| Q3 24 | 7.7% | 0.1% | ||
| Q2 24 | 7.4% | 0.1% |
现金转化率ASIXCLOV
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | 6.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
CLOV
暂无分部数据
